Dr. Ashley Schenk discusses mavacamten and obstructive hypertrophic cardiomyopathy.
0:00-0:28: Intro
0:29-1:09: Introduction of Dr. Ashley Schenk
1:10-5:55: Trial overview
5:56-8:36: Overview of obstructive hypertrophic cardiomyopathy
8:37-10:23: Pharmacological therapy used in patients with obstructive hypertrophic cardiomyopathy and why mavacamten is different
10:24-11:14: Initial thoughts about the trial
11:15-13:30: Beta-blocker subgroup analysis and disopyramide exclusion
13:31-15:05: Adverse effect profile
15:06-16:09: Where do we anticipate mavacamten to fit in this patient population?
16:10-16:49: Final thoughts
16:50-17:26: Closing
References:
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020; 396: 759-69.
CardioScripts 